Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

BIVI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.00%

Insider Buying (Last 12 Months): $17,800.00

Insider Selling (Last 12 Months): $0.00

BioVie Insider Trading History Chart

BioVie Share Price & Price History

^$3.18

▼ -0.18 (-5.36%)

As of 11/21/2024 04:00 PM ET

Days: 30 | 90 | 365

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

BioVie Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/30/2023	Cuong V Do	CEO	Buy	10,000	$1.78	$17,800.00	68,759
9/5/2023	Steve Gorlin	Director	Sell	8,560	$3.05	$26,108.00	75,680
8/22/2023	Richard J Berman	Director	Sell	10,805	$3.50	$37,817.50	16,789
6/7/2023	Richard J Berman	Director	Sell	5,984	$5.81	$34,767.04	23,210
5/22/2023	Richard J Berman	Director	Sell	5,000	$6.50	$32,500.00	29,194
3/27/2023	Richard J Berman	Director	Sell	3,371	$8.52	$28,720.92	41,807
12/7/2021	Joanne Wendy Kim	CFO	Buy	2,000	$5.40	$10,800.00

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

SEC Filings (Institutional Ownership Changes) for BioVie (NASDAQ:BIVI)

4.59% of BioVie stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BioVie Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/14/2024	Sheaff Brock Investment Advisors LLC	51,400	$27K	0.0%	+276.9%	0.129%
5/7/2024	CVI Holdings LLC	599,897	$0.32M	0.3%	N/A	1.503%
11/7/2023	Jump Financial LLC	10,000	$34K	0.0%	N/A	0.027%
10/30/2023	Summit Trail Advisors LLC	10,100	$34K	0.0%	N/A	0.027%
10/25/2023	Crescent Grove Advisors LLC	11,000	$38K	0.0%	N/A	0.030%
10/24/2023	Bank of New York Mellon Corp	15,955	$54K	0.0%	-51.2%	0.043%
8/29/2023	Garde Capital Inc.	24,163	$0.10M	0.0%	+40.8%	0.066%
7/20/2023	AJ Wealth Strategies LLC	23,474	$0.10M	0.0%	+52.2%	0.065%
7/11/2023	FNY Investment Advisers LLC	8,986	$38K	0.0%	N/A	0.025%
5/4/2023	Barclays PLC	54,117	$0.44M	0.0%	+117.7%	0.150%
4/28/2023	AJ Wealth Strategies LLC	15,428	$0.13M	0.0%	N/A	0.043%
2/24/2023	Garde Capital Inc.	17,163	$0.13M	0.0%	N/A	0.049%
2/14/2023	683 Capital Management LLC	16,110	$0.13M	0.0%	N/A	0.053%
2/14/2023	swisspartners Ltd.	294,346	$2.29M	2.9%	+82.8%	0.964%
2/7/2023	Commonwealth Equity Services LLC	12,175	$94K	0.0%	N/A	0.040%
2/1/2023	Bank of Montreal Can	10,000	$78K	0.0%	N/A	0.033%
1/30/2023	International Assets Investment Management LLC	10,500	$82K	0.0%	N/A	0.034%
1/10/2023	FNY Investment Advisers LLC	14,200	$0.11M	0.2%	N/A	0.047%
11/15/2022	Pura Vida Investments LLC	36,617	$91K	0.0%	N/A	0.120%
5/4/2022	swisspartners Ltd.	10,367	$1.87M	1.3%	-87.1%	0.042%
2/14/2022	Long Focus Capital Management LLC	20,000	$90K	0.0%	N/A	0.080%
11/16/2021	swisspartners Ltd.	80,521	$0.54M	0.4%	+45.0%	0.323%
11/12/2021	Renaissance Technologies LLC	53,100	$0.36M	0.0%	+90.3%	0.214%
8/13/2021	Renaissance Technologies LLC	27,900	$0.47M	0.0%	N/A	0.200%
8/13/2021	Geode Capital Management LLC	22,898	$0.39M	0.0%	+8.0%	0.164%
8/13/2021	Vanguard Group Inc.	97,804	$1.66M	0.0%	+267.6%	0.700%
8/11/2021	swisspartners Ltd.	55,521	$0.94M	0.7%	+2.2%	0.397%
5/18/2021	Millennium Management LLC	23,107	$0.45M	0.0%	-3.7%	0.166%
5/17/2021	Ameriprise Financial Inc.	90,876	$1.76M	0.0%	N/A	0.651%
5/12/2021	Geode Capital Management LLC	21,200	$0.41M	0.0%	N/A	0.152%
5/12/2021	swisspartners Ltd.	54,300	$1.05M	0.9%	-27.6%	0.390%
5/7/2021	Sowell Financial Services LLC	2,000	$26K	0.0%	N/A	0.014%
3/11/2021	swisspartners Ltd.	75,000	$1.28M	1.1%	N/A	0.539%
2/16/2021	HN Saltoro Capital LP	15,000	$0.26M	0.1%	N/A	0.108%

Data available starting January 2016

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Today's Range

Now: $3.18

$3.00

$3.43

50 Day Range

MA: $2.28

$1.10

$3.51

52 Week Range

Now: $3.18

$1.04

$58.20

Volume

2,597,806 shs

Average Volume

1,691,754 shs

Market Capitalization

$29.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Who are the company insiders with the largest holdings of BioVie?: BioVie's top insider investors include:
Steve Gorlin (Director)
Cuong V Do (CEO)
Richard J Berman (Director)
Learn More about top insider investors at BioVie.

This company will win the AI race